share_log

Illumina | ARS: Annual Report to Security Holders

Illumina | ARS: Annual Report to Security Holders

Illumina | ARS:年度报告
美股SEC公告 ·  04/05 04:28

Moomoo AI 已提取核心信息

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its annual financial results for the fiscal year ended December 31, 2023. The company reported a 2% decrease in revenue, totaling $4.5 billion compared to $4.6 billion in the previous year. This decline was attributed to a decrease in sequencing consumables revenue and sequencing instruments revenue, partially offset by an increase in service and other revenue. Gross margin also saw a decrease from 64.8% in 2022 to 60.9% in 2023, primarily due to lower manufacturing volumes and the launch of the NovaSeq X platform. Illumina recorded a net loss of $1.161 billion for the year, a significant improvement from the $4.404 billion loss in 2022. The loss from operations was $1.069 billion, compared to a $4.179 billion loss in the previous...Show More
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced its annual financial results for the fiscal year ended December 31, 2023. The company reported a 2% decrease in revenue, totaling $4.5 billion compared to $4.6 billion in the previous year. This decline was attributed to a decrease in sequencing consumables revenue and sequencing instruments revenue, partially offset by an increase in service and other revenue. Gross margin also saw a decrease from 64.8% in 2022 to 60.9% in 2023, primarily due to lower manufacturing volumes and the launch of the NovaSeq X platform. Illumina recorded a net loss of $1.161 billion for the year, a significant improvement from the $4.404 billion loss in 2022. The loss from operations was $1.069 billion, compared to a $4.179 billion loss in the previous year. The company's effective tax rate was negative, at (3.9)%, mainly due to the impact of the goodwill impairment related to its GRAIL reporting unit. Illumina's acquisition of GRAIL, a healthcare company focused on early cancer detection, is still subject to ongoing legal proceedings, and the company announced plans to divest GRAIL. The financial results also included a $712 million goodwill impairment charge for the GRAIL reporting unit. Illumina ended the year with $1.048 billion in cash and cash equivalents, a decrease from $2.011 billion at the end of 2022, after repaying term notes and convertible senior notes totaling $1.25 billion.
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 公布了截至2023年12月31日的财年的年度财务业绩。该公司报告收入下降了2%,总额为45亿美元,而去年同期为46亿美元。这一下降归因于测序消耗品收入和测序仪器收入的减少,但部分被服务和其他收入的增加所抵消。毛利率也从2022年的64.8%下降到2023年的60.9%,这主要是由于制造量下降和NovaSeq X平台的推出。Illumina全年净亏损11.61亿美元,较2022年的44.04亿美元亏损有了显著改善。运营亏损为10.69亿美元,而去年同期亏损为41.79亿美元。该公司的有效税率为负,为(3.9)%,这主要是由于...展开全部
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 公布了截至2023年12月31日的财年的年度财务业绩。该公司报告收入下降了2%,总额为45亿美元,而去年同期为46亿美元。这一下降归因于测序消耗品收入和测序仪器收入的减少,但部分被服务和其他收入的增加所抵消。毛利率也从2022年的64.8%下降到2023年的60.9%,这主要是由于制造量下降和NovaSeq X平台的推出。Illumina全年净亏损11.61亿美元,较2022年的44.04亿美元亏损有了显著改善。运营亏损为10.69亿美元,而去年同期亏损为41.79亿美元。该公司的有效税率为负,为(3.9)%,这主要是由于与其GRAIL报告单位相关的商誉减值的影响。Illumina对专注于癌症早期发现的医疗保健公司GRAIL的收购仍在进行中的法律诉讼中,该公司宣布了剥离GRAIL的计划。财务业绩还包括GRAIL报告部门7.12亿美元的商誉减值费用。Illumina在偿还了总额为12.5亿美元的定期票据和可转换优先票据后,年底的现金及现金等价物为10.48亿美元,低于2022年底的20.11亿美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息